Ultragenyx Pharmaceutical (RARE) Cost of Revenue (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Cost of Revenue for 9 consecutive years, with $30.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 3.45% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $110.3 million (up 24.72% YoY), while the FY2025 annual figure was $109.0 million, up 41.56% from the prior year.
• Cost of Revenue climbed to $30.0 million in Q1 2026 per RARE's latest filing, from $29.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $30.0 million in Q1 2026 and bottomed at $5.3 million in Q4 2022.
• Historically, Cost of Revenue has averaged $17.0 million across 5 years, with a median of $17.2 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 163.71% — and 2026, when it advanced 3.45%.
• Ultragenyx Pharmaceutical's Cost of Revenue stood at $5.3 million in 2022, then jumped by 122.64% to $11.8 million in 2023, then soared by 44.96% to $17.2 million in 2024, then soared by 70.95% to $29.3 million in 2025, then increased by 2.23% to $30.0 million in 2026.
• Business Quant data shows RARE's Cost of Revenue at $30.0 million in Q1 2026, $29.3 million in Q4 2025, and $28.0 million in Q3 2025.